Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Singapore · Delayed Price · Currency is SGD · Price in USD

2.850

+0.050 (1.79%)

Jul 21, 2026, 3:43 PM SGT

14.46% (1Y)

Market Cap	4.95B +13.7%
Revenue (ttm)	930.06M -25.5%
Net Income	407.47M -1.6%
EPS	0.53 -1.9%
Shares Out	n/a
PE Ratio	12.14
Forward PE	n/a
Dividend	0.89 (24.28%)
Ex-Dividend Date	Jun 29, 2026

Volume	98,600
Open	2.820
Previous Close	2.800
Day's Range	2.820 - 2.870
52-Week Range	2.480 - 3.750
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 15, 2026

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Li... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1915

Employees 3,890

Stock Exchange Singapore Exchange

Ticker Symbol T14

Financial Performance

In 2025, SGX:T14's revenue was 4.92 billion, a decrease of -32.70% compared to the previous year's 7.31 billion. Earnings were 2.13 billion, a decrease of -4.41%.

Financial numbers in CNY Financial Statements